A LinkedIn post from Sequel Med Tech highlights plans for an industry session at ATTD 2026 focused on real-world data for its twiist automated insulin delivery system. The session is set to cover metrics such as time-in-range performance and early user experience, with healthcare providers discussing how these findings are being applied in clinical practice.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For investors, the emphasis on real-world evidence suggests Sequel Med Tech is seeking to validate twiist’s clinical utility beyond controlled trials and to position the system within routine care pathways. Strong real-world performance and clinician engagement could support future market adoption, reimbursement arguments, and differentiation in the competitive automated insulin delivery segment.
The focus on time-in-range analyses aligns with evolving standards in diabetes management, which may resonate with payers and providers evaluating cost-effectiveness and outcomes. If the ATTD 2026 data are favorable and broadly disseminated, the event could contribute to building clinical credibility and potentially strengthen the company’s commercial prospects in the medium term.